Preparation and optimization of telmisartan loaded solid lipid nanoparticles by central composite design

Abstract

Background: Glioblastoma multiforme, commonly known as "glioblastoma," is a rapidly expanding tumor that originates from astrocytes, cells that aid in maintaining the health of brain cells called neuronal cells. Developing, testing, and refining telmisartan solid lipid nanoparticles was the primary objective of the research.

Methods: The fluid injection method was employed to create telmisartan solid lipid nanoparticles. The surfactant was Tween 80, and the lipid was palmitic acid. The drug:lipid ratio and surfactant concentration, which are the formulation's independent factors, were compared to the percentage of drug release and the efficiency of trapping, which are the dependent variables. There were twelve distinct formulations that were evaluated.

Results: To prove that the medication and excipients were compatible, researchers utilized differential scanning calorimetry and Fourier transform infrared spectroscopy. The various telmisartan solid lipid nanoparticles were only a few nanometers in size, yet they were all excellent in enclosing pharmaceuticals and continued to release them for up to twenty-four hours. Scanning electron microscopy revealed the distinctive spherical form of telmisartan solid lipid nanoparticles.

Conclusion: The results of this study show that solid lipid nanoparticles might be a good way to get telmisartan to the brain to treat glioblastoma multiforme.